GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » 3-Year FCF Growth Rate

DexTech Medical AB (XSAT:DEX) 3-Year FCF Growth Rate : -43.50% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is DexTech Medical AB 3-Year FCF Growth Rate?

DexTech Medical AB's Free Cash Flow per Share for the three months ended in Mar. 2024 was kr0.01.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -43.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 1.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 11 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of DexTech Medical AB was 35.70% per year. The lowest was -43.50% per year. And the median was -2.50% per year.


Competitive Comparison of DexTech Medical AB's 3-Year FCF Growth Rate

For the Biotechnology subindustry, DexTech Medical AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexTech Medical AB's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's 3-Year FCF Growth Rate falls into.



DexTech Medical AB 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


DexTech Medical AB  (XSAT:DEX) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


DexTech Medical AB 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of DexTech Medical AB's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


DexTech Medical AB (XSAT:DEX) Business Description

Traded in Other Exchanges
N/A
Address
Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a strong clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.

DexTech Medical AB (XSAT:DEX) Headlines